Rebecca Arend
University of Alabama at Birmingham
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Rebecca Arend as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:21 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04606914 · Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal CancerUniversity of Alabama at Birmingham · recruiting · Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer · principal investigator
- Ph1NCT03944902 · CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer PatientsUniversity of Alabama at Birmingham · terminated · Ovarian Cancer, Resistant BRCA Wild-Type Ovarian Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:21 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:21 UTC. The ranking covers the 200 most relevant of 20 PubMed records, and a shared surname and initials can bring in a namesake. All 20 on PubMed
- A Ketogenic Diet Reduces Central Obesity and Serum Insulin in Women with Ovarian or Endometrial Cancer.J Nutr · 2018128 citationsRCR 4.8
- 90 citationsRCR 3.4
- Treating oppositional defiant disorder in primary care: a comparison of three models.J Pediatr Psychol · 200869 citationsRCR 2.9
- A Ketogenic Diet Is Acceptable in Women with Ovarian and Endometrial Cancer and Has No Adverse Effects on Blood Lipids: A Randomized, Controlled Trial.Nutr Cancer · 202053 citationsRCR 2.4
- 45 citationsRCR 1.7
- Predictor and moderator effects in the treatment of oppositional defiant disorder in pediatric primary care.J Pediatr Psychol · 200839 citationsRCR 1.6
- Metabolism of tryptophan and niacin in oral contraceptives users receiving controlled intakes of vitamin B6.Am J Clin Nutr · 197536 citationsRCR 1.8
- DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.Gynecol Oncol · 202325 citationsRCR 2.3
- Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect.Gynecol Oncol · 202021 citationsRCR 0.8
- Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018).J Clin Oncol · 202420 citationsRCR 1.9